Analyst Consensus ?
ConsensusHold27 ratings
Bullish1244.4%
Neutral1451.9%
Bearish13.7%
Sanofi · SNY · FY2025 Q3 · Calendar Q4 2025
Sanofi’s Q3 growth leaned on Dupixent and launches as vaccines faced pressure
Sanofi’s near-term growth case rests on continued Dupixent demand and contributions from newer launches, but vaccine softness, pricing pressure and pipeline execution remain important offsets.
Reported Before market openNASDAQHealthcare
$106.90B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$1.70
Consensus $1.60
EPS surprise
+6.2%
Reported versus consensus
Reported revenue
$15.43B
Consensus $11.11B
Revenue surprise
+38.9%
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
+4.3%
Event window
SPY move
+0.8%
Same window
Abnormal move
+3.5%
Stock minus SPY
Volume
1.2×
Versus trailing sessions
Subsequent drift
-3.9%
Up to 20 sessions
SNYSPY benchmark
Ask FN2 about SNY FY2025 Q3
Transcript, numbers and history already loaded
Why did SNY rise 4.3% after beating EPS estimates in FY2025 Q3?What changed in SNY's guidance and outlook in FY2025 Q3?Give me the bull and bear case for SNY after FY2025 Q3 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
The Q3 analysis shows sales growth supported by Dupixent and new launches, while lower flu immunization rates and price cuts weighed on vaccines. Management maintained its full-year 2025 outlook, consistent with the prior quarter.
Guidance delta
Maintained: full-year 2025 sales growth guidance remained high single-digit, and EPS growth guidance remained low double-digit, according to the Q3 transcript analysis.
Key takeaways
- Q3 sales grew 7% to €12.4 billion, with Dupixent and newer launches leading growth.
- New products represented 15% of total sales; Ayvakit, Nuvaxovid and Wayrilz were identified as contributors.
- Vaccine sales faced lower flu immunization rates and pricing pressure, especially in Germany.
- Management reaffirmed its 2025 sales and EPS growth outlook.
Management priorities
- Expand Dupixent into additional indications and continue rollout of newer products.
- Advance pipeline programs, including amlitelimab, brivekimig, venglustat and tolebrutinib.
- Continue selective capital allocation, including bolt-on acquisitions, dividends and share buybacks.
- Expand insulin affordability programs and global health partnerships.
Follow SNY with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$45.55Current
$48.07Low
$53.84Average
$64High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 3, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Morgan Stanley | Equal Weight | Overweight | Downgrade | May 1, 2026 |
| Exane BNP Paribas | Neutral | Outperform | Downgrade | Apr 20, 2026 |
| B of A Securities | Neutral | Buy | Downgrade | Feb 12, 2026 |
| UBS | Neutral | Buy | Downgrade | Jan 16, 2026 |
| Barclays | Equal Weight | Overweight | Downgrade | Jan 6, 2026 |
| Guggenheim | Neutral | Buy | Downgrade | Dec 9, 2025 |
| JP Morgan | Neutral | Overweight | Downgrade | Dec 8, 2025 |
| Deutsche Bank | Buy | Hold | Upgrade | Sep 2, 2025 |
| Argus Research | Buy | Buy | Maintain | Jul 26, 2024 |
| SVB Leerink | Outperform | Market Perform | Upgrade | Sep 27, 2021 |
| Goldman Sachs | Buy | Neutral | Upgrade | Mar 11, 2020 |
| Argus | Buy | Buy | Maintain | Nov 8, 2018 |
| Bank of America | Buy | Neutral | Upgrade | Sep 10, 2018 |
| Citigroup | Buy | Neutral | Upgrade | Aug 10, 2018 |
| HSBC | Hold | Reduce | Upgrade | Aug 30, 2017 |
| Bryan Garnier | Neutral | Buy | Downgrade | Nov 9, 2015 |
| Bernstein | Market Perform | Outperform | Downgrade | Nov 9, 2015 |
| Leerink Swann | Outperform | Market Perform | Upgrade | Mar 17, 2015 |
| Jefferies | Hold | Buy | Downgrade | Oct 29, 2014 |
| S&P Capital IQ | Hold | Buy | Downgrade | Jan 9, 2014 |
| Kepler Cheuvreux | Buy | Hold | Upgrade | Nov 18, 2013 |
| Mirabaud Securities | Buy | Neutral | Upgrade | Nov 15, 2013 |
| Mirabaud | Buy | Neutral | Upgrade | Nov 15, 2013 |
| Natixis | Buy | Neutral | Upgrade | Oct 31, 2013 |
| Cowen & Co. | Market Perform | Outperform | Downgrade | Aug 21, 2013 |
| Banco Sabadell | Sell | Buy | Downgrade | May 3, 2013 |
| Standpoint Research | Hold | Buy | Downgrade | Aug 3, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $45.55. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Morgan Stanley | Sarita Kapila | $49 | $42.98 | +7.6% | Jul 8, 2026 |
| Morgan Stanley | Analyst unavailable | $52 | $46.08 | +14.2% | May 1, 2026 |
| BNP Paribas | Peter Verdult | $50 | $48.06 | +9.8% | Apr 20, 2026 |
| Morgan Stanley | Sarita Kapila | $56 | $49.19 | +22.9% | Jun 2, 2025 |
| Berenberg Bank | Luisa Hector | $64 | $58.51 | +40.5% | Sep 10, 2024 |
| Argus Research | Jasper Hellweg | $60 | $52.54 | +31.7% | Jul 26, 2024 |
| Argus Research | Jasper Hellweg | $55 | $48 | +20.7% | Apr 3, 2024 |
| Barclays | Iain Simpson | $48.07 | $48.17 | +5.5% | Dec 21, 2022 |
Track every rating change on SNY the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationSanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases.…
Historical context
All SNY earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| NBIX Neurocrine Biosciences, Inc. | FY2026 Q3 · Calendar Q4 2026 | +72.3% | -0.5% | Neurocrine Raises INGREZZA Outlook as Core Products Grow |
| AXSM Axsome Therapeutics, Inc. | FY2026 Q3 · Calendar Q4 2026 | +60.6% | -5.8% | Axsome’s Q3 growth broadens, while reimbursement and trial execution remain key tests |
| TEM Tempus AI, Inc. | FY2026 Q3 · Calendar Q4 2026 | +174.7% | +8.7% | Tempus Q3 growth broadens across diagnostics and data |
| IDXX IDEXX Laboratories, Inc. | FY2026 Q3 · Calendar Q4 2026 | — | +19.5% | IDEXX raises 2026 outlook as diagnostics, placements and software support growth |
| AZN AstraZeneca PLC | FY2026 Q3 · Calendar Q4 2026 | +7.3% | +7.0% | AstraZeneca pairs solid growth with pipeline investment and restructuring |
| BTSG BrightSpring Health Services, Inc. Common Stock | FY2026 Q3 · Calendar Q4 2026 | +14.2% | +11.1% | BrightSpring posts strong Q3 growth while maintaining guidance |
Latest beats and misses
Who reports nextBeat on EPS
- MARFY2026 Q3 · November 2, 2026+6.3% EPS+4.3% move
- NBIXFY2026 Q3 · November 2, 2026+72.3% EPS-0.5% move
- AXSMFY2026 Q3 · November 2, 2026+60.6% EPS-5.8% move
- TEMFY2026 Q3 · November 2, 2026+174.7% EPS+8.7% move
- BWXTFY2026 Q3 · November 2, 2026+6.8% EPS-0.2% move
- CUBEFY2026 Q3 · October 29, 2026+2.3% EPS+4.0% move
Missed on EPS
- RYAAYFY2027 Q2 · November 2, 2026-0.3% EPS+2.9% move
- GLPIFY2026 Q3 · October 29, 2026-11.5% EPS-1.3% move
- LYBFY2026 Q3 · October 30, 2026-1.2% EPS+5.0% move
- CCJFY2026 Q3 · October 30, 2026-101.4% EPS-7.9% move
- VALEFY2026 Q3 · October 29, 2026-24.6% EPS+1.9% move
- PINSFY2026 Q3 · October 29, 2026-5.4% EPS-2.8% move
Get the SNY recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars · 2026-11-03T00:40:42.339249+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-03T00:40:42.336367+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-11-03. For educational purposes only; not investment advice.